Journal: Cancer Medicine

Article Title: Schedule-dependent therapeutic efficacy of L19mTNF-α and melphalan combined with gemcitabine

doi: 10.1002/cam4.89

Figure Lengend Snippet: Administration schedules of gemcitabine (G) and L19mTNF-α/melphalan (L-M) as single or combined treatments

Article Snippet: WEHI-164 mouse fibrosarcoma (3 × 10 6 ) (ECACC, Sigma-Aldrich, Milan, Italy) and K7M2 mouse osteosarcoma (0.3 × 10 6 ) (American Type Culture Collection, Rockville, MD), all BALB/c origin, were subcutaneously (s.c.) implanted in the left flank of 8- to 10-week-old immunocompetent syngeneic BALB/c mice, purchased from Harlan UK (Oxon, U.K.).

Techniques: In Vivo

Journal: Cancer Medicine

Article Title: Schedule-dependent therapeutic efficacy of L19mTNF-α and melphalan combined with gemcitabine

doi: 10.1002/cam4.89

Figure Lengend Snippet: Therapeutic efficacy of the different schedules of drugs administration. Tumor-free survival curves (%) versus time (days) of WEHI-164 (A and B) and K7M2 (C and D) tumor-bearing mice subjected to G-G (black triangles), L-M (black circles), G-L-M-G (black asterisks), or L-M-G-G (black squares) administration schedules. Data are illustrative of at least 10 mice per treatment group.

Article Snippet: WEHI-164 mouse fibrosarcoma (3 × 10 6 ) (ECACC, Sigma-Aldrich, Milan, Italy) and K7M2 mouse osteosarcoma (0.3 × 10 6 ) (American Type Culture Collection, Rockville, MD), all BALB/c origin, were subcutaneously (s.c.) implanted in the left flank of 8- to 10-week-old immunocompetent syngeneic BALB/c mice, purchased from Harlan UK (Oxon, U.K.).

Techniques: Drug discovery

Journal: Cancer Medicine

Article Title: Schedule-dependent therapeutic efficacy of L19mTNF-α and melphalan combined with gemcitabine

doi: 10.1002/cam4.89

Figure Lengend Snippet: Immune population involved in WEHI-164 and K7M2 tumor eradication in in vivo -depleted mice. Tumor-free survival curves (%) versus time (days) of the WEHI-164 and K7M2 tumor-bearing mice subjected to G-G treatment, in vivo depleted with antibodies direct with CD4 + or CD8 + T cells as described in the Materials and Methods section. The tumor-free survival of groups of five WEHI-164 (A) and K7M2 (B) tumor-bearing mice subjected to G-G treatment (open squares), co-CD4-depleted (black triangles), co-CD8-depleted (black asterisks), or untreated tumor-bearing mice (black diamonds) is indicated. Specific cytolytic activity of the immune splenocytes after WEHI-164 and K7M2 tumor cure and persistence of antitumor memory. Specific lysis (%) of WEHI-164 (C) and K7M2 (D) cells by different E:T ratio of splenocytes from WEHI-164- and K7M2-cured mice at 6 months after G-G (open squares) or L-M-G-G (black diamonds) treatment and after s.c. tumor challenge. The specific lysis is totally inhibited by anti-MHC class I antibodies (open diamonds) and unaffected by anti-MHC class II antibodies (black asterisks). Results are representative of three independent 51 Chromium-release experiments with similar results. (E) The ability of WEHI-164- and K7M2-cured mice subjected to G-G and L-M-G-G treatments to reject the first tumor challenge at different times post cure. The number of challenged mice is indicated in round brackets.

Article Snippet: WEHI-164 mouse fibrosarcoma (3 × 10 6 ) (ECACC, Sigma-Aldrich, Milan, Italy) and K7M2 mouse osteosarcoma (0.3 × 10 6 ) (American Type Culture Collection, Rockville, MD), all BALB/c origin, were subcutaneously (s.c.) implanted in the left flank of 8- to 10-week-old immunocompetent syngeneic BALB/c mice, purchased from Harlan UK (Oxon, U.K.).

Techniques: In Vivo, Activity Assay, Lysis

Journal: Cancer Medicine

Article Title: Schedule-dependent therapeutic efficacy of L19mTNF-α and melphalan combined with gemcitabine

doi: 10.1002/cam4.89

Figure Lengend Snippet: Immunohistochemical assessment of tumor infiltrates. Immunohistochemical assessment of CD4 + T cells, CD8 + T cells, and Gr-1 + CD11b + MDSCs in untreated or treated WEHI-164 (A–C) and K7M2 (D–F) tumor-bearing mice 3 days after the conclusion of all therapeutic protocols. Untreated group of mice received PBS only. Results are expressed as cell number (mean ± SD) per high-magnification microscopic field (HMMF). Data are representative of at least three mice per each treatment group. *** P ≤ 0.001; ** P ≤ 0.01; * P ≤ 0.05.

Article Snippet: WEHI-164 mouse fibrosarcoma (3 × 10 6 ) (ECACC, Sigma-Aldrich, Milan, Italy) and K7M2 mouse osteosarcoma (0.3 × 10 6 ) (American Type Culture Collection, Rockville, MD), all BALB/c origin, were subcutaneously (s.c.) implanted in the left flank of 8- to 10-week-old immunocompetent syngeneic BALB/c mice, purchased from Harlan UK (Oxon, U.K.).

Techniques: Immunohistochemical staining

Journal: Cancer Medicine

Article Title: Schedule-dependent therapeutic efficacy of L19mTNF-α and melphalan combined with gemcitabine

doi: 10.1002/cam4.89

Figure Lengend Snippet: Tumor volume assessment after the different therapeutic treatments. Three days after the term of the all therapeutic protocols, the tumor volumes of WEHI-164 and K7M2 untreated and treated tumor-bearing mice were compared. Untreated mice received PBS only. Tumor volumes (cm 3 ) are expressed as mean ± SD. Data are illustrative of least 10 mice per each treatment group.

Article Snippet: WEHI-164 mouse fibrosarcoma (3 × 10 6 ) (ECACC, Sigma-Aldrich, Milan, Italy) and K7M2 mouse osteosarcoma (0.3 × 10 6 ) (American Type Culture Collection, Rockville, MD), all BALB/c origin, were subcutaneously (s.c.) implanted in the left flank of 8- to 10-week-old immunocompetent syngeneic BALB/c mice, purchased from Harlan UK (Oxon, U.K.).

Techniques:

Journal: Cancer Medicine

Article Title: Schedule-dependent therapeutic efficacy of L19mTNF-α and melphalan combined with gemcitabine

doi: 10.1002/cam4.89

Figure Lengend Snippet: Flow-cytometric assessment of regulatory T cells

Article Snippet: WEHI-164 mouse fibrosarcoma (3 × 10 6 ) (ECACC, Sigma-Aldrich, Milan, Italy) and K7M2 mouse osteosarcoma (0.3 × 10 6 ) (American Type Culture Collection, Rockville, MD), all BALB/c origin, were subcutaneously (s.c.) implanted in the left flank of 8- to 10-week-old immunocompetent syngeneic BALB/c mice, purchased from Harlan UK (Oxon, U.K.).

Techniques: